Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTBVAC Phase 1b/2a safety, immunogenicity, and dose-escalation study in adults
PACTR201709002547410Phase 2Not yet recruiting
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Jan 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Tuberculosis (TB) comparing MTBVAC with BCG comparator (2 arms). Primary endpoint: Safety and reactogenicity of MTBVAC at escalating dose levels compared to BCG vaccine. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
mtbvacbcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201709002547410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201709002547410.